公司概覽
業務類別 --
業務概覽 Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
公司地址 46, Avenue de la Great Army, Paris, FRA, 75017
電話號碼 +33 153774000
傳真號碼 +33 153774303
公司網頁 https://www.sanofi.com
員工數量 74846
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Mr. Manuela Buxo Executive Vice President, Specialty Care -- 17/02/2026
Mr. Roy Papatheodorou Executive Vice President and General Counsel -- 17/02/2026
Mr. Emmanuel Frenehard Executive Vice President and Chief Digital Officer -- 17/02/2026
Mr. Houman Ashrafian Executive Vice President and Head of Research and Development -- 17/02/2026
Mr. Brendan O'Callaghan Executive Vice President, Global Manufacturing and Supply -- 17/02/2026
Mr. Francois-Xavier Roger Executive Vice President and Chief Financial Officer -- 17/02/2026
Ms. Natalie Bickford Executive Vice President and Chief People Officer -- 17/02/2026
Ms. Audrey Duval Executive Vice President, Corporate Affairs -- 17/02/2026
Mr. Olivier Charmeil Executive Vice President, General Medicines and Interim Chief Executive Officer -- 17/02/2026
Ms. Madeleine Roach Executive Vice President, Business Operations -- 17/02/2026
Mr. Thomas Triomphe Executive Vice President, Vaccines -- 17/02/2026
 
董事會成員
董事會 職務 更新日期
Mr. Emile Voest Independent Director 17/02/2026
Ms. Barbara Lavernos Director 17/02/2026
Mr. Wolfgang Laux Director 17/02/2026
Ms. Clotilde Delbos Independent Director 17/02/2026
Ms. Carole Ferrand Independent Director 17/02/2026
Ms. Rachel Duan Independent Director 17/02/2026
Dr. Antoine Yver, M.D.,M.Sc. Independent Director 17/02/2026
Mr. John Sundy Independent Director 17/02/2026
Mr. Christophe Babule Director 17/02/2026
Ms. Anne-Francoise Nesmes Independent Director 17/02/2026
Mr. Patrick Kron Independent Director 17/02/2026
Mr. Humberto De Sousa Director 17/02/2026
Mr. Paul Hudson Director 17/02/2026
Mr. Frederic Oudea Chairman of the Board 17/02/2026
Ms. Lise Kingo Independent Director 17/02/2026
Mr. Jean-Paul Kress, M.D. Independent Director 17/02/2026
 
所屬ETF (更新日期: 07/03/2026 03:14)
代號 名稱 佔比% 持有日期
JFLIJPMorgan Flexible Income ETF0.0001%27/02/2026
REFAColumbia Research Enhanced Intl Eq ETF0.00005%28/02/2026
PQNTPictet AI Enhanced International Eq ETF0.00005%27/02/2026
PBDMInvesco PureBeta FTSE Dev ex-NrthAmr ETF0.00004%31/05/2023
IGAVoya Global Advantage and Premium Opp0.00004%31/01/2026
DXIVDimensional International Vector Eq ETF0.00003%27/02/2026
IBFRInnovator International Dev Mgd 10BfrETF0.00002%25/02/2026
RFEUFirst Trust RiverFront Dynamic Eurp ETF0.00002%08/01/2026
EAFGPacer Developed Mkts Csh Cow Gr Ldr ETF0.00001%27/02/2026
DEEFXtrackers FTSE Develop ex US Mulfact ETF0.00001%24/02/2026
IDVYFirst Trust International Ris Div AchETF0.000004%26/02/2026
AOMiShares Core 40/60 Moderate Allc ETF<0.000001%27/02/2026
BDYNiShares Dynamic Equity Active ETF<0.000001%31/05/2025
BIDDiShares International Dividend ActiveETF<0.000001%11/02/2026
DMCYDemocracy International<0.000001%10/02/2026
EEAEuropean Equity Fund<0.000001%31/12/2025
FEGEFirst Eagle Global Equity ETF<0.000001%05/08/2025
FEOEFirst Eagle Overseas Equity ETF<0.000001%13/08/2025
GLOFiShares Global Equity Factor ETF<0.000001%28/02/2026
HAWXiShares Currency Hdgd MSCI ACWI exUS ETF<0.000001%26/02/2026
  1    2    3    4    5    6    7   8    9  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.